NeuroKey-3™
A Fully Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers Linked to Neurodegeneration
Neurodegeneration Biomarkers
The available treatments for neurodegenerative diseases are restricted, and the effective advancement of innovative therapeutics in the future, as well as the assessment of their effectiveness beyond traditional cognitive tests, will heavily depend on an optimal biomarker strategy for the identification, monitoring, and stratification of these diseases.
However, assay development and biomarker validation for current offerings is a costly and laborious process, most of which do not meet the criteria for regulatory submission.
To address these challenges, Inoviv developed NeuroKey-3™, a proprietary assay that utilizes analytical algorithms, workflows, and internal standards, providing high reproducibility, robustness, sensitivity, and a linear dynamic range over six orders of magnitude. This offers absolute quantification at low pg/ml concentration following immunoprecipitation-based enrichment (IP-MS) in a hybrid assay format.
Associated with cognitive decline and involved in synaptic plasticity
Xiang, Yang et al. “Neurogranin: A Potential Biomarker of Neurological and Mental Diseases.” Frontiers in aging neuroscience vol. 12 584743. 6 Oct. 2020, doi:10.3389/fnagi.2020.584743
Liu, W., Lin, H., He, X. et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry 10,125 (2020). https://doi.org/10.1038/s41398-020-0801-2
Essential in neuronal survival & growth
Bathina, Siresha, and Undurti N Das. “Brain-derived neurotrophic factor and its clinical implications.” Archives of medical science : AMS vol. 11,6 (2015): 1164-78. doi:10.5114/aoms.2015.56342
Mediates neuroinflammation in the CNS
Felderhoff-Mueser, Ursula et al. “IL-18: a key player in neuroinflammation and neurodegeneration.” Trends in neurosciences vol. 28,9 (2005): 487-93. doi:10.1016/j.tins.2005.06.008
Accelerating Clinical Trial Timelines
Obtain definitive insights into your research goals
- Post-Translational Modifications (PTMs)
- Lipids
- Metabolites
- Highly robust and reproducible
- Absolute quantification of multiple proteins in a single IP-MS assay
- Statistical Analysis
- Graphical Data Representation
- Correlation Matrices
- Quantitative Values
End-to-End Solution
The Biomarker Strategy for Success
Measure proteins which pharmaceutical companies care about, at the precision needed to enable decision-making and FDA submissions in three easy steps
Send
Samples
After designing your custom experimental assay with our with our proteomics experts, send your human plasma samples to our CLIA, FDA inspected (US) or GCP/GLP (UK) certified labs
Bioinformatics and Validation
After processing samples, our bioinformatics team analyzes data through proprietary analytical algorithms, workflows and internal standards to provide the highest possible reproducibility and robustness following FDA bioanalytical guidelines.
Clinical Utility
Proceed to clinical trials or laboratory developed tests (LDT) if needed. We offer extended validation for exploratory & secondary end points.
